Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares hit a new 52-week high during mid-day trading on Tuesday after B. Riley raised their price target on the stock from $26.00 to $32.00. B. Riley currently has a buy rating on the stock. Arrowhead Pharmaceuticals traded as high as $25.04 and last traded at $25.04, with a volume of 6718 shares trading hands. The stock had previously closed at $24.04.
Other research analysts also recently issued research reports about the company. BidaskClub upgraded Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Cantor Fitzgerald set a $24.00 price objective on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 12th. Chardan Capital restated a “buy” rating and issued a $24.50 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 11th. Finally, Piper Jaffray Companies upped their price objective on Arrowhead Pharmaceuticals from $25.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, April 16th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $24.86.
In other news, General Counsel Patrick O’brien sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $24.88, for a total transaction of $746,400.00. Following the transaction, the general counsel now owns 203,000 shares of the company’s stock, valued at approximately $5,050,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bruce D. Given sold 42,500 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $19.99, for a total value of $849,575.00. Following the transaction, the chief operating officer now directly owns 687,106 shares in the company, valued at approximately $13,735,248.94. The disclosure for this sale can be found here. Insiders have sold a total of 149,571 shares of company stock worth $3,156,537 in the last ninety days. Insiders own 4.80% of the company’s stock.
The company has a market cap of $2.37 billion, a PE ratio of -38.45 and a beta of 2.15.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. Arrowhead Pharmaceuticals had a return on equity of 6.72% and a net margin of 10.09%. The company had revenue of $48.15 million for the quarter, compared to analyst estimates of $45.78 million. On average, equities research analysts forecast that Arrowhead Pharmaceuticals Inc will post 0.68 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Arrowhead Pharmaceuticals (ARWR) Reaches New 1-Year High After Analyst Upgrade” was first published by Rockland Register and is the sole property of of Rockland Register. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://rocklandregister.com/2019/05/30/arrowhead-pharmaceuticals-arwr-reaches-new-1-year-high-after-analyst-upgrade.html.
Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Further Reading: Why is insider trading harmful?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.